About
Technology
Issues
FAQ
Links
Official Page
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.